Lymphoma Diagnosis and Evaluation

Understanding biopsies, PET scans, and blood analysis.

Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Diagnosis and Evaluation of Lymphoma

Diagnosis and evaluation are the cornerstone steps that determine the success of lymphoma treatment. Whether you are a patient seeking care abroad or a referring physician, understanding the process helps set realistic expectations and facilitates coordinated care. Lymphoma accounts for roughly 3% of all cancers worldwide, and early, accurate assessment can dramatically improve outcomes. This page walks you through every stage of the diagnostic journey—from the first clinical interview to sophisticated molecular profiling—highlighting the expertise available at Liv Hospital for international patients.

Our multidisciplinary team combines state‑of‑the‑art imaging, precise pathology, and cutting‑edge genetic analysis to create a personalized treatment roadmap. Throughout the evaluation, patients receive dedicated support services, including interpreter assistance, travel coordination, and comfortable accommodation, ensuring a seamless experience from arrival to discharge.

Read on to discover how each component of lymphoma diagnosis and evaluation works, what you can expect during your visit to Istanbul, and why Liv Hospital is uniquely positioned to deliver world‑class oncologic care.

Understanding Lymphoma: Types and Staging

Lymphoma is a heterogeneous group of malignancies arising from lymphocytes, the white blood cells that orchestrate immune responses. The two main categories are Hodgkin lymphoma (HL) and non‑Hodgkin lymphoma (NHL), each with distinct biological behavior and therapeutic approaches. Accurate classification begins with a thorough review of clinical presentation, imaging findings, and tissue pathology.

Key Subtypes

Hodgkin lymphoma: Characterized by Reed‑Sternberg cells; most common in young adults.
Diffuse large B‑cell lymphoma (DLBCL): The most frequent NHL subtype, aggressive but often curable.
Follicular lymphoma: Indolent NHL, typically managed with watchful waiting or targeted therapy.
Peripheral T‑cell lymphoma: Rare, aggressive, requiring specialized regimens.

Staging Systems

Staging determines disease extent and guides treatment intensity. The Ann Ann Arbor system, supplemented by modern imaging, remains the standard:

Stage	Description
I	Single lymph node region or a single extralymphatic organ.
II	Two or more lymph node regions on the same side of the diaphragm.
III	Lymph node regions on both sides of the diaphragm.
IV	Disseminated involvement of one or more extralymphatic organs.

Each stage may be further qualified with “A” (no systemic symptoms) or “B” (presence of fever, night sweats, or weight loss). Precise staging is integral to the overall diagnosis and evaluation pathway, influencing both prognosis and therapeutic choice.

Initial Clinical Assessment

The diagnostic journey starts with a detailed medical history and physical examination performed by an oncologist experienced in hematologic malignancies. This encounter gathers essential information that shapes subsequent investigations.

History Taking

Duration and pattern of lymphadenopathy.
Systemic B‑symptoms (fever, night sweats, weight loss).
Previous infections, autoimmune disorders, or immunosuppressive therapy.
Family history of cancer or genetic syndromes.
Exposure to environmental risk factors (e.g., pesticides, viruses).

Physical Examination

Clinicians assess:

Size, consistency, and tenderness of palpable lymph nodes.
Spleen and liver enlargement.
Skin lesions or ulcerations that might suggest cutaneous lymphoma.

During this phase, patients receive a clear explanation of the planned diagnostic steps, timelines, and any preparatory instructions (e.g., fasting before imaging). Liv Hospital’s international patient coordinators ensure that language barriers do not impede understanding, providing translated materials and live interpreter services as needed.

Imaging Techniques in Diagnosis

Imaging plays a pivotal role in the diagnosis and evaluation of lymphoma by revealing the anatomical distribution of disease, guiding biopsies, and monitoring treatment response. Liv Hospital offers a full suite of advanced modalities.

Positron Emission Tomography–Computed Tomography (PET‑CT)

PET‑CT combines metabolic and anatomical data, making it the gold standard for staging and response assessment. Fluorodeoxyglucose (FDG) uptake highlights active disease, allowing detection of both nodal and extranodal involvement.

Magnetic Resonance Imaging (MRI)

MRI is preferred for central nervous system involvement or when radiation exposure must be minimized. Diffusion‑weighted imaging adds functional insight, improving lesion characterization.

Ultrasound and Conventional CT

High‑resolution ultrasound guides fine‑needle aspirations of superficial nodes, while contrast‑enhanced CT provides rapid whole‑body surveys, especially valuable in emergency settings.

Below is a comparison of the main imaging modalities used in lymphoma work‑up:

Modality	Strengths	Limitations
PET‑CT	High sensitivity for active disease; whole‑body coverage.	Radiation dose; limited in low‑grade lymphomas with low FDG uptake.
MRI	Excellent soft‑tissue contrast; no ionizing radiation.	Longer scan time; higher cost.
CT	Fast; widely available.	Radiation exposure; less functional information.
Ultrasound	Real‑time guidance; cost‑effective.	Operator dependent; limited depth penetration.

Our radiology team follows international standards, ensuring that each image set is interpreted by subspecialists in oncologic imaging, thereby enhancing the overall diagnosis and evaluation accuracy.

Laboratory and Pathology Tests

Laboratory investigations complement imaging by providing biochemical and cellular clues about lymphoma activity. Tissue diagnosis remains the definitive step in confirming the disease.

Blood Work

Complete blood count (CBC) – evaluates anemia, leukocytosis, or thrombocytopenia.
Lactate dehydrogenase (LDH) – an indirect marker of tumor burden.
Beta‑2 microglobulin – prognostic indicator, especially in NHL.
Serology for viral agents (EBV, HIV, Hepatitis C) that may be associated with specific lymphoma subtypes.

Biopsy Techniques

Obtaining adequate tissue is essential for histopathologic classification and molecular testing.

Excisional lymph node biopsy: Preferred for most cases; provides intact architecture.
Core needle biopsy: Useful for deep or inaccessible nodes under imaging guidance.
Fine‑needle aspiration (FNA): Often combined with flow cytometry for rapid assessment.

Pathology Evaluation

Experienced hematopathologists apply immunohistochemistry (IHC) panels to differentiate lymphoma subtypes. Key markers include CD20, CD3, CD30, BCL2, and Ki‑67. The pathology report integrates morphological findings with IHC patterns, delivering a definitive diagnosis that fuels the broader diagnosis and evaluation framework.

Advanced Molecular and Genetic Evaluation

Modern oncology increasingly relies on molecular insights to refine prognosis and tailor therapy. Liv Hospital’s molecular laboratory offers a range of assays that deepen the diagnostic picture.

Fluorescence In Situ Hybridization (FISH)

FISH detects chromosomal translocations such as t(14;18) in follicular lymphoma or MYC rearrangements in aggressive B‑cell lymphomas, informing risk stratification.

Next‑Generation Sequencing (NGS) Panels

Targeted NGS evaluates mutations in genes like MYD88, EZH2, and TP53. The results guide the selection of novel agents, including BTK inhibitors or immune checkpoint blockers.

Gene Expression Profiling

For DLBCL, the cell‑of‑origin classification (GCB vs. ABC) predicts response to specific chemotherapy regimens and emerging targeted therapies.

Below is a simplified overview of molecular tests commonly ordered during lymphoma diagnosis and evaluation:

Test	Purpose	Clinical Impact
FISH	Identify translocations	Risk assessment, eligibility for targeted therapy.
NGS	Detect somatic mutations	Personalized drug selection.
Gene Expression Profiling	Determine cell‑of‑origin	Predict chemotherapy response.
Flow Cytometry	Immunophenotyping of cells	Rapid classification of lymphoma type.

Our integrated pathology‑molecular team reviews all results in a tumor board setting, ensuring that each patient’s therapeutic plan reflects the most current scientific evidence.

Multidisciplinary Planning and Follow‑up

After completing the comprehensive diagnosis and evaluation, the case proceeds to a multidisciplinary tumor board where hematologists, radiologists, pathologists, surgeons, and supportive‑care specialists collaborate.

Treatment Decision Process

Review of staging, imaging, and molecular data.
Discussion of patient preferences, comorbidities, and logistical considerations.
Selection of first‑line therapy (e.g., chemo‑immunotherapy, targeted agents, or stem‑cell transplant).
Establishment of a personalized follow‑up schedule, including surveillance imaging and laboratory monitoring.

Patient-Centered Support

Liv Hospital assigns a dedicated international patient coordinator who assists with visa arrangements, airport transfers, and accommodation near the hospital campus. Interpreter services are available throughout the treatment journey, ensuring clear communication of the diagnostic findings and therapeutic options.

Regular follow‑up visits incorporate repeat imaging, blood tests, and, when indicated, minimal‑invasive biopsies to assess remission status or detect early relapse. This systematic approach guarantees that the initial diagnosis and evaluation continues to inform care decisions long after the first appointment.

Why Choose Liv Hospital

Liv Hospital combines JCI accreditation, a multidisciplinary oncology team, and cutting‑edge technology to deliver world‑class lymphoma care to patients from around the globe. Our 360‑degree international patient services cover everything from airport pickup to interpreter‑supported consultations, ensuring a stress‑free experience in Istanbul. With a proven track record in complex hematologic malignancies, we provide personalized treatment plans grounded in the latest scientific evidence.

Ready to start your personalized lymphoma assessment? Contact Liv Hospital’s International Patient Office today to schedule a virtual consultation and begin your journey toward effective treatment.

Book a Free Certified Online
Doctor Consultation

Related Doctors

Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology

Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology

Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology

Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology

Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Spec. MD. Ceyda Aslan Hematology

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Minure Abışova Eliyeva Hematology

Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Reviews from 9,651

4,9

Worth a look

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

FREQUENTLY ASKED QUESTIONS

What are the main types of lymphoma?

The Ann Arbor system classifies lymphoma from stage I (single region) to stage IV (disseminated disease) and adds an “A” or “B” suffix for the presence of systemic B‑symptoms. Modern imaging, especially PET‑CT, refines staging by detecting metabolically active disease throughout the body, which guides treatment intensity.

How is lymphoma staged?

What imaging modalities are used for lymphoma diagnosis?

PET‑CT provides whole‑body metabolic imaging and is the gold standard for staging and response assessment. MRI offers superior soft‑tissue contrast, useful for CNS involvement or when radiation must be avoided. Contrast‑enhanced CT gives rapid anatomic surveys, while high‑resolution ultrasound guides needle biopsies of superficial nodes.

Which laboratory and pathology tests confirm lymphoma?

Baseline labs include CBC, LDH, beta‑2 microglobulin, and viral serologies. Tissue diagnosis is obtained via excisional lymph node biopsy (preferred), core needle biopsy, or fine‑needle aspiration with flow cytometry. Pathology labs apply immunohistochemistry panels (e.g., CD20, CD3, CD30, Ki‑67) to define the lymphoma subtype.

How do molecular tests influence lymphoma treatment?

FISH detects translocations such as t(14;18) in follicular lymphoma or MYC rearrangements in aggressive B‑cell lymphomas, informing risk stratification. Targeted NGS panels reveal mutations (MYD88, EZH2, TP53) that can direct the use of BTK inhibitors or checkpoint blockers. Gene expression profiling, especially for DLBCL, distinguishes germinal‑center B‑cell (GCB) from activated B‑cell (ABC) subtypes, predicting chemotherapy response.

What support does Liv Hospital provide for international lymphoma patients?

The hospital’s international patient coordinators handle travel logistics, arrange interpreter‑supported consultations, and provide translated medical documents. Patients stay in comfortable, hospital‑affiliated lodging, and a dedicated coordinator ensures seamless communication throughout diagnosis, treatment planning, and follow‑up.